RAIN Rain Therapeutics Inc.

FDA Catalyst Company
2.6
-0.07  -3%
Previous Close 2.67
Open 2.74
52 Week Low 2.22
52 Week High 22.22
Market Cap $68,977,683
Shares 26,529,878
Float 6,508,898
Enterprise Value $-51,958,227
Volume 10,156
Av. Daily Volume 65,898
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Oppenheimer Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/01/2022
Guggenheim Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/18/2021
Piper Sandler Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/18/2021
Goldman Sachs Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/18/2021
Citigroup Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/18/2021

Latest News

  1. NEWARK, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NASDAQ:RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics, today announced it will be presenting three posters highlighting its oral mouse double minute 2 (MDM2) inhibitor, milademetan, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois, June 3–7, 2022.

    Additional presentation details can be found below:

    Title: Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan
    Abstract Number: 3136
    Presenter: Vijaya G. Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA
    Poster Session:
    View Full Article
  2. – Quarter-end cash position of $123.2 million provides ample cash runway into first half of 2024 –

    – Phase 3 MANTRA topline data expected earlier than previously guided, now in first half of 2023, with enrollment anticipated to be completed by end of 2022 –

    – Phase 2 MANTRA-2 trial on-track with interim data anticipated in fourth quarter 2022 –

    – Based on enrollment progress from ongoing clinical studies, Phase 2 MANTRA-3 trial in Merkel cell carcinoma and Phase 1/2 MANTRA-4 basket trial for CDKN2A-loss advanced solid tumors in combination with atezolizumab, both on track to commence in fourth quarter 2022 –

    – Management to host conference call and webcast today at 5:00 PM Eastern Time –

    NEWARK, Calif., May 04, 2022 (GLOBE…

    View Full Article
  3. NEWARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NASDAQ:RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the first quarter ended March 31, 2022 and highlights of recent progress on Wednesday, May 4, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results.

    Conference Call and Webcast Details:
    Date: May 4, 2022
    Time: 2:00-3:00 pm PT (5:00-6:00 pm ET)
    Dial In Numbers: 1 (877) 300-8521 (U.S. Toll Free) / 1 (412) 317-6026 (International)

    Conference ID: 10166166

    Webcast Link: https://services.choruscall.com/mediaframe/webcast.html?webcastid=yOa8KoUv

    View Full Article
  4. NEWARK, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NASDAQ:RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics, today announced a poster presentation and two trials in progress at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from April 8-13, 2022.

    Poster Presentation Title:Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors
    Abstract Number:1174 / 4
    Presenter:Vijaya G. Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA
    Poster Session Date and Time:Monday, April 11, 2022, 9:00 a.m. – 12:30 p.m. CT
    Location:Poster Section 27
      
    Trial
    View Full Article
  5. – Quarter-end cash position of $140.2 million provides runway to complete all ongoing and planned clinical trials of milademetan, including an ample cash cushion for the Phase 3 MANTRA trial in liposarcoma –

    – Enrollment in both Phase 3 liposarcoma trial (MANTRA) and Phase 2 basket trial (MANTRA-2) are on schedule, all site activations anticipated by the end of the first quarter 2022 –

    – Rain entered into a clinical supply agreement with Roche for the supply of atezolizumab for a planned Phase 1 trial (MANTRA-4) combination study of milademetan and atezolizumab in patients with CDKN2A loss and p53 wildtype advanced cancers –

    – Management to host conference call and webcast today at 4:30 PM Eastern Time –

    NEWARK, Calif., March 03, 2022…

    View Full Article
View All Rain Therapeutics Inc. News